Evotec stock trades against weak earnings and delisting pressure as 2024 guidance stays intact

Evotec stock reflects a difficult 2024 after a cyberattack, a US delisting announcement, and weaker nine month 2024 earnings, while management keeps full year guidance and restructures the business.

Evotec AG (ISIN DE0005664809) stock encapsulates a turbulent period for the German drug discovery specialist, with a sharp profit decline in the first nine months of 2024 and a confirmed delisting from the US Nasdaq market weighing on sentiment, even as full year guidance remains intact according to company disclosures in late 2024. The company, whose shares are primarily traded on Xetra in Frankfurt, continues to emphasize its long term collaborative research model despite short term earnings pressure and the financial aftermath of a 2023 cyberattack.

Revenue up in 2023 despite cyberattack impact

According to Evotec's 2023 annual report, the company generated total revenue of about EUR 781 million in fiscal 2023, an increase of roughly 15 percent compared with around EUR 668 million in 2022, with growth driven mainly by its contract research and development services. In the same 2023 period, Evotec reported adjusted EBITDA of approximately EUR 54 million, down from roughly EUR 101 million in 2022, as costs related to the spring 2023 cyberattack and higher research investments weighed on profitability. The company also highlighted that by the end of 2023 it had a cash and investment position in the mid hundreds of millions of euros, providing a buffer to continue funding discovery projects with its partners across neurology, oncology, and metabolic disease.

Management indicated in its 2023 reporting that the cyberattack temporarily disrupted some laboratory operations and data infrastructure but that most affected systems were restored during the year, with insurance and mitigation measures limiting the long term operational impact. For investors, the key question coming out of 2023 was whether the company could rebuild margins back toward the roughly EUR 100 million adjusted EBITDA level seen in 2022 while maintaining double digit revenue growth.

Revenue up 17 percent in the first nine months of 2024

In its nine month 2024 update, Evotec reported that group revenue rose to approximately EUR 602 million for the first three quarters of 2024, compared with around EUR 514 million in the same period of 2023, equivalent to growth of about 17 percent year on year. The company explained that this increase came primarily from a higher volume of discovery and development services for large pharmaceutical partners, as well as contributions from milestone and license payments tied to progress in partnered drug candidates. The nine month 2024 figures show that Evotec maintained a double digit expansion in its top line despite restructuring activities and the lingering effect of 2023 operational disruptions.

However, Evotec also disclosed that adjusted EBITDA for the first nine months of 2024 deteriorated markedly to around minus EUR 35 million, compared with a positive adjusted EBITDA of about EUR 47 million for the same period in 2023, as restructuring charges, inflationary cost pressure, and continued investments into proprietary pipeline projects compressed profitability. This swing of more than EUR 80 million between the positive nine month 2023 adjusted EBITDA and the negative nine month 2024 figure underscores how much the earnings profile has weakened over the past year, even though revenue has continued to grow.

Management nonetheless confirmed its full year 2024 guidance in that update, indicating that it still expected revenue in a corridor roughly in line with the nine month run rate and an adjusted EBITDA outcome that would likely remain under pressure but benefit from cost savings in the final quarter of the year. The guidance confirmation signaled that the company saw no need for a profit warning despite the deep nine month EBITDA swing into negative territory.

Delisting from Nasdaq and focus on Frankfurt listing

Alongside the earnings headwinds, Evotec announced in 2024 that it would voluntarily delist its American Depositary Shares from the Nasdaq stock market, concentrating trading in its ordinary shares on the Frankfurt Stock Exchange. The company stated that the decision reflected a desire to reduce the regulatory and administrative costs associated with maintaining a dual listing, including SEC reporting, in a phase when management is focused on stabilizing operations and profitability. For US based investors, the delisting means that future trading exposure to Evotec will primarily come through the German listing and potentially over the counter instruments rather than a direct Nasdaq quote.

The strategic implications of this move are significant because a Nasdaq listing can provide broader visibility in North America and access to certain index products, while its removal may reduce liquidity in US hours and alter the shareholder base. Evotec's management has argued that the cost savings from eliminating the duplicate listing obligations and the possibility of a more concentrated investor communication effort in Europe outweigh these disadvantages for the current stage of the company.

Collaborative business model with pharma partners

Evotecs business model is built on discovery alliances and development partnerships with large pharmaceutical and biotechnology companies, in which it supplies integrated research services from target identification to preclinical and early clinical development. This model aims to generate recurring service revenue while also capturing upside through milestone and royalty payments when partnered drug candidates progress toward approval. In 2023, the majority of the companys EUR 781 million revenue came from these co owned and fee for service arrangements, reflecting both the scale of its platform and the breadth of its customer base.

The company has invested heavily in so called multimodality platforms, including small molecules, biologics, gene therapies, and cell based modalities, and it operates research sites across Germany, France, the United Kingdom, and the United States. By the end of 2023, Evotec reported that it had dozens of preclinical and clinical stage assets under partnership, which, if successful, could generate additional milestones and royalties that would supplement its service revenue. However, the timing and probability of success for such assets are uncertain, and the near term financial profile continues to be dominated by contracted research income and associated operating costs.

Profitability challenges and restructuring efforts

The sharp deterioration in adjusted EBITDA in the first nine months of 2024 highlights that Evotec has struggled to translate revenue growth into sustainable profits in the recent period. While the revenue base increased from about EUR 514 million in the first nine months of 2023 to approximately EUR 602 million in the same period of 2024, the adjusted EBITDA line moved from a positive EUR 47 million to a negative roughly EUR 35 million. This indicates that cost growth and restructuring charges outpaced the additional contribution margin from higher revenues.

In its 2024 updates, the company pointed to several drivers for the weaker profitability, including ongoing integration expenses from previous acquisitions, footprint adjustments in certain locations, and higher personnel and energy costs. Evotec has initiated restructuring measures intended to streamline its site network and focus resources on the most productive partnerships and platforms. Management expects that these actions will gradually lower the fixed cost base, but in the short term they have added to operating expenses and weighed on reported margins.

For investors monitoring Evotec stock, the trajectory of adjusted EBITDA and free cash flow over the next several reporting periods will be central to assessing whether the restructuring is sufficient to restore profitability closer to the 2022 level of about EUR 101 million in adjusted EBITDA. The experience of 2023 and the first nine months of 2024 shows that high revenue growth alone is not enough to secure value creation if the cost structure is not closely controlled.

Liquidity profile and investment capacity

Evotec entered 2024 with a sizable liquidity buffer, thanks to its cash and investments position at the end of 2023, which stood in the mid hundreds of millions of euros according to its annual report. This financial position provides room for the company to continue funding internal pipeline programs and capital expenditures without relying immediately on external equity financing. It also offers resilience against short term volatility in milestone and license revenues, which can fluctuate depending on the timing of partner decisions and clinical trial outcomes.

At the same time, the combination of negative adjusted EBITDA in the first nine months of 2024 and ongoing capital needs for platform maintenance and expansion means that Evotec must demonstrate a credible path to improved margins and cash generation to avoid a gradual erosion of its cash position. Investors in research driven outsourcing businesses often scrutinize the balance between growth investments and disciplined capital allocation, particularly when profit metrics deteriorate even as revenue grows at a double digit rate.

Implications for Evotec stock valuation

From a valuation perspective, Evotec stock is influenced by several competing factors. On one hand, the increase in revenue from approximately EUR 668 million in 2022 to about EUR 781 million in 2023 and then to roughly EUR 602 million for the first nine months of 2024 underscores the continuing demand from pharmaceutical clients for external discovery and development capacity. On the other hand, the swing in adjusted EBITDA from EUR 101 million in 2022 to EUR 54 million in 2023 and then to around minus EUR 35 million for the first nine months of 2024 raises questions about the sustainability of the business model at the current cost structure.

The announced delisting from Nasdaq may also affect the valuation framework because it could change the composition of the shareholder base, reduce exposure to certain growth oriented US investors, and modestly lower trading liquidity. Some market participants may view the move as a sign that Evotec is deprioritizing the North American capital markets, while others may see it as a pragmatic response to cost and complexity without meaningful impact on the underlying operations, which remain centered in Europe.

Representative discovery service platforms

One of Evotecs core offerings is its integrated discovery service platform, which combines high throughput screening, medicinal chemistry, structural biology, and in vitro and in vivo pharmacology to support clients in identifying and optimizing lead compounds. These platforms are designed to help partners reduce the time and cost required to move from target identification to candidate selection by leveraging Evotecs existing infrastructure and expertise. In fiscal 2023, a significant portion of the companys EUR 781 million in revenue was attributable to such discovery and preclinical development services, reflecting their importance in the overall business mix.

In recent years, Evotec has also expanded its capabilities into biologics and cell therapy discovery, recognizing that many new therapeutic modalities require different technologies and expertise than traditional small molecule drugs. The company has invested in automated cell handling systems, high content imaging, and advanced bioanalytics to support these areas, which it expects to be drivers of future revenue growth. As these newer modalities scale up, they may also carry different margin profiles compared with the more established small molecule services, which could either help or hinder the overall profitability trajectory depending on the pricing and cost dynamics.

Evotec stock and recent market context

On the Frankfurt Stock Exchange, Evotec stock continues to trade as a mid cap life science name, and the companys market capitalization has oscillated in recent years in line with changes in earnings expectations and risk appetite for biotech related equities. The combination of the 2023 cyberattack, the subsequent pressure on adjusted EBITDA, and the 2024 Nasdaq delisting decision has shaped recent investor sentiment and contributed to a more cautious stance among some market participants.

For many observers, the key metrics to watch in upcoming Evotec disclosures will be the pace of revenue growth relative to the 2022 and 2023 baselines, the development of adjusted EBITDA from the nine month 2024 level of about minus EUR 35 million, and any updates to the capital allocation and listing strategy. Together, these factors will help determine how Evotec stock is assessed in terms of risk and reward within the broader European biotech and research services landscape.

Evotec at a glance

• Company: Evotec AG
• ISIN: DE0005664809
• WKN: 566480
• Ticker: XETRA: EVT
• Trading venue: Xetra
• Sector / Industry: Health Care / Biotechnology and research services
• Index membership: MDAX